Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study.Tailored Therapy for Hodgkin Lymphoma Based on Predefined Risk Factors and Early Interim PET/CT for Response Assessment and Further Therapy Decisions.

NCT00392314 is registered in ClinicalTrials.gov with Rambam Health Care Campus as lead sponsor.

NCT NCT00392314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00392314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study.Tailored Therapy for Hodgkin Lymphoma Based on Predefined Risk Factors and Early Interim PET/CT for Response Assessment and Further Therapy Decisions.
Lead sponsor
Rambam Health Care Campus
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2006
Completion date
May 31, 2014
Enrollment
365 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma